Revvity (NYSE:RVTY) Rating Increased to Buy at Wall Street Zen

Revvity (NYSE:RVTY) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. lifted their price target on Revvity from $100.00 to $105.00 and gave the company a “neutral” rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $129.00 price objective on shares of Revvity in a report on Tuesday, February 3rd. Wells Fargo & Company upped their price target on shares of Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. Bank of America lowered shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price target on the stock. in a report on Monday, December 15th. Finally, TD Cowen reissued a “hold” rating on shares of Revvity in a research note on Tuesday, February 3rd. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $113.67.

Revvity Stock Performance

NYSE RVTY opened at $98.23 on Friday. The firm’s fifty day moving average price is $103.31 and its two-hundred day moving average price is $96.41. The stock has a market cap of $10.98 billion, a PE ratio of 47.23, a PEG ratio of 2.10 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. Revvity has a fifty-two week low of $81.36 and a fifty-two week high of $120.39.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $772.06 million for the quarter, compared to the consensus estimate of $759.81 million. Revvity had a return on equity of 7.92% and a net margin of 8.45%.Revvity’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $1.42 EPS. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, equities analysts expect that Revvity will post 4.94 EPS for the current fiscal year.

Institutional Trading of Revvity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVTY. AQR Capital Management LLC raised its stake in Revvity by 5.2% during the 1st quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock worth $883,000 after buying an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Revvity by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock valued at $1,246,000 after acquiring an additional 744 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Revvity by 102.0% during the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock valued at $7,343,000 after acquiring an additional 35,048 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Revvity by 45.5% during the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after purchasing an additional 189,871 shares during the period. Finally, Focus Partners Wealth raised its position in shares of Revvity by 13.0% during the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock worth $744,000 after purchasing an additional 811 shares during the period. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.